Clinical trial

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

NCT06876675

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Lorlatinib Normalized identity: lorlatinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Design: OBSERVATIONAL · Status: ENROLLING BY INVITATION · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusENROLLING_BY_INVITATION

Study typeOBSERVATIONAL

Start date2024-10-15

PhaseN/A

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Hyperlipidemiaverified · MONDO: hyperlipidemia

Interventions

LorlatinibDRUG · verified · RxNorm: lorlatinib

Sponsors & collaborators

Peking University Third Hospitallead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06876675 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.